• Ongoing phase 1/2 study with up to 64 patients
  • The patients have received 1–4 earlier lines of therapy including IMiDs and PIs
  • Demonstrates how melflufen can be administered as a combination therapy with daratumumab or bortezomib
  • Explores potential for using melflufen in earlier lines of therapy
  • May significantly increase melflufen’s market potential as a combination therapy
  • Started in Q2 2018, data reporting in 2018/2019, with the results from phase 1 and phase 2 expected in 2019 and 2020, respectively